NASDAQ:CALC

CalciMedica Q4 2024 Earnings Results & Report

CalciMedica logo
$1.17 -0.05 (-4.10%)
Closing price 04:00 PM Eastern
Extended Trading
$1.16 -0.01 (-0.85%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CalciMedica beat analyst earnings expectations in its Q4 2024 results, released March 27, 2025. The company reported EPS of -$1.70 versus the -$2.40 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens

CalciMedica EPS Results

Actual EPS
-$1.70
Consensus EPS
-$2.40
Beat/Miss
Beat by +$0.70
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

CalciMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

CalciMedica Q4 2024 Earnings FAQ

CalciMedica (NASDAQ:CALC) reported earnings of -$1.70 per share for Q4 2024, beating the consensus estimate of -$2.40. The report was announced on Thursday, March 27, 2025.

CalciMedica Earnings Headlines

FY2026 EPS Estimates for CalciMedica Raised by HC Wainwright
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
CalciMedica (CALC) Set to Release Earnings on Wednesday
See More CalciMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email.

About CalciMedica

CalciMedica (NASDAQ:CALC) is a clinical-stage biopharmaceutical company developing treatments for serious inflammatory and immunologic conditions. Its research focuses on calcium release-activated calcium (CRAC) channels, which play a role in immune-cell activity and inflammation.

The company’s lead drug candidate, Auxora, is an investigational CRAC channel inhibitor being studied for acute inflammatory conditions, including acute pancreatitis. CalciMedica has no marketed products; its candidates remain in clinical development.

Based in La Jolla, California, CalciMedica became a publicly traded company in 2024 through a business combination with Orion Acquisition Corp. The company’s work is centered on developing and testing its therapies, rather than commercial product sales.

View CalciMedica Profile